Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00956436 · ClinicalTrials.gov registry record · Phase 1
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00956436 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 40 participants.
The verdict
NCT00956436, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
Interventions
- DRUG Sorafenib
- DRUG BIIB022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00956436
The ClinicalTrials.gov registry entry for NCT00956436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00956436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00956436 about?
NCT00956436 is a clinical study titled "Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)". This is a phase 1b, open-Label study of sorafenib with BIIB022 in subjects with advanced hepatocellular carcinoma.
What is the current status of trial NCT00956436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00956436?
The interventions under investigation include: Sorafenib (DRUG), BIIB022 (DRUG).
Who is sponsoring clinical trial NCT00956436?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.